Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema.
Stroke is one of the major causes of morbidity and mortality in the world. Stroke is complicated by brain edema and other pathophysiological events. Among the most important players in the development and evolution of stroke-evoked brain edema is the hormone arginine-vasopressin and its receptors, V1a and V2. Recently, the V1a and V2 receptor blocker conivaptan has been attracting attention as a potential drug to reduce brain edema after stroke. However, animal models which involve conivaptan applications in stroke research need to be modified based on feasible routes of administration. Here the outcomes of 48 hr continuous intravenous (IV) are compared with intraperitoneal (IP) conivaptan treatments after experimental stroke in mice. We developed a protocol in which middle cerebral artery occlusion was combined with catheter installation into the jugular vein for IV treatment of conivaptan (0.2 mg) or vehicle. Different cohorts of animals were treated with 0.2 mg bolus of conivaptan or vehicle IP daily. Experimental stroke-evoked brain edema was evaluated in mice after continuous IV and IP treatments. Comparison of the results revealed that the continuous IV administration of conivaptan alleviates post-ischemic brain edema in mice, unlike the IP administration of conivaptan. We conclude that our model can be used for future studies of conivaptan applications in the context of stroke and brain edema.
Neurotrauma Research, Swedish Medical Center; Emil.Zeynalov@healthonecares.com.
Emil
E
Zeynalov
Neurotrauma Research, Swedish Medical Center.
Susan M
SM
Jones
Neurosurgery, Colorado Brain and Spine Institute.
J Paul
JP
Elliott
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists / Q000008:administration & dosage*; D001552:Benzazepines / Q000008:administration & dosage*; D001929:Brain Edema / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D020244:Infarction, Middle Cerebral Artery; D007262:Infusions, Intravenous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D017483:Receptors, Vasopressin / Q000378:metabolism; D020521:Stroke / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology
D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D017483:Receptors, Vasopressin; C106389:conivaptan
Appl Microbiol. 1969 Feb;17(2):250-1
5775909
Am J Physiol Cell Physiol. 2012 Feb 1;302(3):C505-17
22049209
Brain Res. 2009 Jul 7;1279:168-73
19446533
Med Lett Drugs Ther. 2006 Jun 19;48(1237):51-2
16785851
J Biol Chem. 2005 Apr 22;280(16):16208-18
15687501
J Cereb Blood Flow Metab. 2006 Mar;26(3):414-20
16049424
Neurocrit Care. 2010 Feb;12(1):124-31
19806476
PLoS One. 2015 Aug 14;10(8):e0136121
26275173
J Neurosci Methods. 2011 Feb 15;195(2):206-10
21168441
Neurocrit Care. 2009;11(1):14-9
19123060
J Cereb Blood Flow Metab. 2005 Aug;25(8):1012-9
15744246
J Pharmacol Exp Ther. 1997 Jul;282(1):1-6
9223533
Curr Protoc Mouse Biol. 2015 Mar 02;5(1):51-63
25727200
CNS Neurosci Ther. 2015 Mar;21(3):271-9
25495836
Stroke. 2004 Jan;35(1):2-6
14684767
Neuropeptides. 2015 Jun;51:55-62
25843346
Neurotherapeutics. 2012 Jan;9(1):65-72
22125096
Crit Care Med. 2008 Sep;36(9):2634-40
18679106
Int J Stroke. 2012 Jul;7(5):398-406
22712741
J Cereb Blood Flow Metab. 2013 Feb;33(2):225-34
23149557
Drugs R D. 2004;5(2):94-7
15293869
Neurotox Res. 2009 Feb;15(2):133-7
19384576